Huang Xiu-Yan, Wang Lu, Huang Zi-Li, Zheng Qi, Li Qi-Song, Tang Zhao-You
Department of General Surgery, The 6th People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, China.
J Cancer Res Clin Oncol. 2009 Sep;135(9):1245-55. doi: 10.1007/s00432-009-0566-8. Epub 2009 Mar 10.
Chinese herbs have become a focus of interest in cancer treatment. This study evaluates the effect of the herbal compound extract "Songyou Yin" (containing Salvia miltiorrhiza Bge.-danshen and other four herbs) on hepatocellular carcinoma (HCC).
Human HCC cell line MHCC97H with high-metastatic potential was employed for in vitro study. In vivo study was conducted in nude mice bearing HCC orthotopic xenograft with MHCC97H.
In vitro, "Songyou Yin" caused dramatic attenuation of tumor proliferation by induction of apoptosis that was associated with caspase-3 activation, and inhibit invasiveness of MHCC97H via reducing matrix metalloproteinase-2 (MMP2) activity. In vivo, "Songyou Yin" minimized cancer-related body weight loss of mice bearing tumors without distinct toxicity, and inhibited tumor growth with stepwise increased dosage of "Songyou Yin" and accorded with the expression of proliferating cell nuclear antigen. Moreover, "Songyou Yin" inhibited tumor growth was associated with an increased TUNEL-positive apoptosis as well as a decreased microvessel density and vascular endothelial growth factor (VEGF) abundance, and inhibited tumor invasion via down-regulation of MMP2. The lung metastatic extent was decreased (p < 0.01, compared with control). The life span of nude mice bearing xenografts was 75.0 +/- 3.9 days in "Songyou Yin" group, whereas it was 52.0 +/- 2.3 days in the control (p < 0.001).
Nontoxic herbal compound extract "Songyou Yin" inhibited tumor growth and prolonged survival, via inducing apoptosis and down-regulation of MMP2 and VEGF, which indicated its potential use in patients with advanced HCC.
中草药已成为癌症治疗领域的研究热点。本研究评估了中药复方提取物“松友饮”(含丹参等五味中药)对肝细胞癌(HCC)的影响。
采用具有高转移潜能的人肝癌细胞系MHCC97H进行体外研究。体内研究则选用接种了MHCC97H肝癌原位移植瘤的裸鼠。
体外实验中,“松友饮”通过诱导凋亡显著抑制肿瘤增殖,这与半胱天冬酶-3的激活相关,并且通过降低基质金属蛋白酶-2(MMP2)的活性抑制MHCC97H的侵袭能力。体内实验中,“松友饮”使荷瘤小鼠的癌症相关体重减轻最小化,且无明显毒性,随着“松友饮”剂量逐步增加,其抑制肿瘤生长的效果增强,这与增殖细胞核抗原的表达情况相符。此外,“松友饮”抑制肿瘤生长与TUNEL阳性凋亡增加、微血管密度降低以及血管内皮生长因子(VEGF)丰度降低相关,并且通过下调MMP2抑制肿瘤侵袭。肺转移程度降低(与对照组相比,p < 0.01)。“松友饮”组接种移植瘤的裸鼠寿命为75.0 ± 3.9天,而对照组为52.0 ± 2.3天(p < 0.001)。
无毒的中药复方提取物“松友饮”通过诱导凋亡以及下调MMP2和VEGF抑制肿瘤生长并延长生存期,表明其在晚期HCC患者中具有潜在应用价值。